Skip to main content
Thank you for visiting nature.com. You are using a browser version
with limited support for CSS. To obtain the best experience, we
recommend you use a more up to date browser (or turn off
compatibility mode in Internet Explorer). In the meantime, to
ensure continued support, we are displaying the site without styles
and JavaScript.
Advertisement
[image]
[image]
•  View all journals
•  
Search
•  Log in
•  Content Explore content
•  About the journal
•  Publish with us
•  Subscribe
•  Sign up for alerts
•  RSS feed
1. nature 
2. nature reviews drug discovery 
3. review articles 
4. article
•  Review Article
•  Published: 07 November 2014


Is there new hope for
therapeutic matrix
metalloproteinase inhibition?
•  Roosmarijn E. Vandenbroucke1,2 &
•  Claude Libert
1,2 
Nature Reviews Drug Discovery volume 13, pages 904–927
(2014)Cite this article
•  31k Accesses
•  749 Citations
•  8 Altmetric
•  Metrics details
Subjects
•  Drug discovery
•  Infectious diseases
•  Metalloproteins
•  Sepsis
Key Points
•  Despite promising preclinical data supporting the blockage of
MMPs as a treatment for cancer, all Phase III cancer trials
failed. This might be due to inadequate clinical trial design,
the characteristics of the MMP inhibitors used, poor
knowledge on the complexity of the MMPs and discrepancies
between the mouse models and the patients enrolled in the
clinical trials.
•  Over the past decade, much knowledge has been accumulated


on the functions of the different MMPs, and better and more
specific MMP inhibitors have been developed. So far,
however, this has not resulted in MMP inhibitors that are
ready for clinical use.
•  The reluctance to therapeutically inhibit MMPs has been
influenced by the failure of the first clinical trials and the
observed side effects, the complexity of the MMPs that exert
both detrimental and beneficial roles and the lack of tools to
dissect the role of a specific MMP in a specific organ. In
addition, the high homology between the MMPs, the
difficulty in identifying substrate specificity and the
discrepancy between in vitro and in vivo identified substrates
impede the development of specific MMP inhibitors.
•  Nevertheless, many data are available from studies of MMP-
knockout mice and on the use of MMP inhibitors in animals
that support therapeutic MMP inhibition in inflammatory
conditions such as systemic inflammatory response syndrome
(SIRS), sepsis and disorders associated with intestinal and
brain inflammation.
•  Based on the currently available data, MMP inhibition has
great therapeutic potential for the treatment of inflammatory
disorders. However, this can only be fully explored once the
MMP functions are unravelled in more detail and potent and
selective MMP inhibitors are available.
Abstract
Matrix metalloproteinases (MMPs) are zinc-dependent
endopeptidases that form a family of 24 members in mammals.
Evidence of the pathological roles of MMPs in various diseases,
combined with their druggability, has made them attractive
therapeutic targets. Initial drug discovery efforts focused on the
roles of MMPs in cancer progression, and more than 50 MMP
inhibitors have been investigated in clinical trials in various
cancers. However, all of these trials failed. Reasons for failure
include the lack of inhibitor specificity and insufficient knowledge


about the complexity of the disease biology. MMPs are also known
to be involved in several inflammatory processes, and there are new
therapeutic opportunities for MMP inhibitors to treat such diseases.
In this Review, we discuss the recent advances made in
understanding the role of MMPs in inflammatory diseases and the
therapeutic potential of MMP inhibition in those conditions.
 Access through your institution
Buy or subscribe
This is a preview of subscription content, access via your institution
Access options
 Access through your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Learn more
Buy this article
•  Purchase on SpringerLink
•  Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during
checkout
Additional access options:
•  Log in
•  Learn about institutional subscriptions


•  Read our FAQs
•  Contact customer support
Figure 1: Schematic overview of the structure of MMP family
members and the relationship with other metzincin
superfamily members.
[image]
Figure 2: Nomenclature of the substrate–protease interaction.
[image]
Figure 3: Overview of the most important MMPs in sepsis.
[image]
Figure 4: Schematic overview of the detrimental activities of
MMPs in IBD.
[image]
Similar content being viewed by others
[image]
Utilizing genetic code expansion to modify N-TIMP2
specificity towards MMP-2, MMP-9, and MMP-14
Article Open access 30 March 2023
[image]
Design of MMP-1 inhibitors via SAR transfer and
experimental validation
Article Open access 03 December 2022
[image]
Identification of novel therapeutic target and
prognostic biomarker in matrix metalloproteinase
gene family in pancreatic cancer
Article Open access 11 October 2023
References


1. Gialeli, C., Theocharis, A. D. & Karamanos, N. K. Roles of
matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278, 16–27 (2011).
Article  CAS  PubMed  Google Scholar 
2. Davies, B., Brown, P. D., East, N., Crimmin, M. J. & Balkwill,
F. R. A synthetic matrix metalloproteinase inhibitor decreases
tumor burden and prolongs survival of mice bearing human
ovarian carcinoma xenografts. Cancer Res. 53, 2087–2091
(1993).
CAS  PubMed  Google Scholar 
3. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix
metalloproteinase inhibitors and cancer: trials and
tribulations. Science 295, 2387–2392 (2002).
Article  CAS  PubMed  Google Scholar 
4. Egeblad, M. & Werb, Z. New functions for the matrix
metalloproteinases in cancer progression. Nature Rev. Cancer
2, 161–174 (2002).
Article  CAS  Google Scholar 
5. Fisher, J. F. & Mobashery, S. Recent advances in MMP
inhibitor design. Cancer Metastasis Rev. 25, 115–136 (2006).
Article  CAS  PubMed  Google Scholar 
6. Overall, C. M. & Kleifeld, O. Towards third generation matrix
metalloproteinase inhibitors for cancer therapy. Br. J. Cancer
94, 941–946 (2006).
Article  CAS  PubMed  PubMed Central  Google Scholar 
7. Overall, C. M. & Kleifeld, O. Tumour microenvironment —
opinion: validating matrix metalloproteinases as drug targets
and anti-targets for cancer therapy. Nature Rev. Cancer 6,
227–239 (2006).


Article  CAS  Google Scholar 
8. Pirard, B. Insight into the structural determinants for selective
inhibition of matrix metalloproteinases. Drug Discov. Today
12, 640–646 (2007).
Article  CAS  PubMed  Google Scholar 
9. Rao, B. G. Recent developments in the design of specific
matrix metalloproteinase inhibitors aided by structural and
computational studies. Curr. Pharm. Design 11, 295–322
(2005).
Article  CAS  Google Scholar 
10. Pavlaki, M. & Zucker, S. Matrix metalloproteinase inhibitors
(MMPIs): the beginning of phase I or the termination of phase
III clinical trials. Cancer Metastasis Rev. 22, 177–203 (2003).
Article  CAS  PubMed  Google Scholar 
11. Overall, C. M. & Lopez-Otin, C. Strategies for MMP inhibition
in cancer: innovations for the post-trial era. Nature Rev.
Cancer 2, 657–672 (2002).
Article  CAS  Google Scholar 
12. Iyer, R. P., Patterson, N. L., Fields, G. B. & Lindsey, M. L. The
history of matrix metalloproteinases: milestones, myths, and
misperceptions. Am. J. Physiol. Heart Circ. Physiol. 303, H919–
H930 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
13. Hadler-Olsen, E., Winberg, J. O. & Uhlin-Hansen, L. Matrix
metalloproteinases in cancer: their value as diagnostic and
prognostic markers and therapeutic targets. Tumour Biol. 34,
2041–2051 (2013).
Article  CAS  PubMed  Google Scholar 
14. Decock, J., Thirkettle, S., Wagstaff, L. & Edwards, D. R.


Matrix metalloproteinases: protective roles in cancer. J. Cell.
Mol. Med. 15, 1254–1265 (2011).
Article  CAS  PubMed  PubMed Central  Google Scholar 
15. Lopez-Otin, C., Palavalli, L. H. & Samuels, Y. Protective roles
of matrix metalloproteinases: from mouse models to human
cancer. Cell Cycle 8, 3657–3662 (2009).
Article  CAS  PubMed  Google Scholar 
16. Vanlaere, I. & Libert, C. Matrix metalloproteinases as drug
targets in infections caused by Gram-negative bacteria and in
septic shock. Clin. Microbiol. Rev. 22, 224–239 (2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 
17. Drummond, A. H. et al. Preclinical and clinical studies of
MMP inhibitors in cancer. Ann. NY Acad. Sci. 878, 228–235
(1999).
Article  CAS  PubMed  Google Scholar 
18. Skiles, J. W., Gonnella, N. C. & Jeng, A. Y. The design,
structure, and clinical update of small molecular weight
matrix metalloproteinase inhibitors. Curr. Med. Chem. 11,
2911–2977 (2004).
Article  CAS  PubMed  Google Scholar 
19. Edwards, D. R., Handsley, M. M. & Pennington, C. J. The
ADAM metalloproteinases. Mol. Aspects Med. 29, 258–289
(2008).
Article  CAS  PubMed  PubMed Central  Google Scholar 
20. Tan Ide, A., Ricciardelli, C. & Russell, D. L. The
metalloproteinase ADAMTS1: a comprehensive review of its
role in tumorigenic and metastatic pathways. Int. J. Cancer
133, 2263–2276 (2013).
Article  PubMed  CAS  Google Scholar 


21. Khokha, R., Murthy, A. & Weiss, A. Metalloproteinases and
their natural inhibitors in inflammation and immunity. Nature
Rev. Immunol. 13, 649–665 (2013).
Article  CAS  Google Scholar 
22. Gross, J. & Lapiere, C. M. Collagenolytic activity in
amphibian tissues: a tissue culture assay. Proc. Natl Acad. Sci.
USA 48, 1014–1022 (1962).
Article  CAS  PubMed  PubMed Central  Google Scholar 
23. Sterchi, E. E. Special issue: metzincin metalloproteinases. Mol.
Aspects Med. 29, 255–257 (2008).
Article  PubMed  Google Scholar 
24. Ra, H. J. & Parks, W. C. Control of matrix metalloproteinase
catalytic activity. Matrix Biol. 26, 587–596 (2007).
Article  CAS  PubMed  PubMed Central  Google Scholar 
25. Fanjul-Fernandez, M., Folgueras, A. R., Cabrera, S. & Lopez-
Otin, C. Matrix metalloproteinases: evolution, gene regulation
and functional analysis in mouse models. Biochim. Biophys.
Acta 1803, 3–19 (2010).
Article  CAS  PubMed  Google Scholar 
26. Butler, G. S. & Overall, C. M. Proteomic identification of
multitasking proteins in unexpected locations complicates
drug targeting. Nature Rev. Drug Discov. 8, 935–948 (2009).
Article  CAS  Google Scholar 
27. Sorokin, L. The impact of the extracellular matrix on
inflammation. Nature Rev. Immunol. 10, 712–723 (2010).
Article  CAS  Google Scholar 
28. Cauwe, B., Van den Steen, P. E. & Opdenakker, G. The
biochemical, biological, and pathological kaleidoscope of cell


surface substrates processed by matrix metalloproteinases.
Crit. Rev. Biochem. Mol. Biol. 42, 113–185 (2007).
Article  CAS  PubMed  Google Scholar 
29. Page-McCaw, A., Ewald, A. J. & Werb, Z. Matrix
metalloproteinases and the regulation of tissue remodelling.
Nature Rev. Mol. Cell Biol. 8, 221–233 (2007).
Article  CAS  Google Scholar 
30. Loffek, S., Schilling, O. & Franzke, C. W. Series “matrix
metalloproteinases in lung health and disease”: biological role
of matrix metalloproteinases: a critical balance. Eur. Respir. J.
38, 191–208 (2011).
Article  CAS  PubMed  Google Scholar 
31. Mannello, F. & Gazzanelli, G. Tissue inhibitors of
metalloproteinases and programmed cell death: conundrums,
controversies and potential implications. Apoptosis 6, 479–
482 (2001).
Article  CAS  PubMed  Google Scholar 
32. Troeberg, L. & Nagase, H. Analysis of TIMP expression and
activity. Methods Mol. Med. 135, 251–267 (2007).
Article  CAS  PubMed  Google Scholar 
33. Nagase, H., Visse, R. & Murphy, G. Structure and function of
matrix metalloproteinases and TIMPs. Cardiovascular Res. 69,
562–573 (2006).
Article  CAS  Google Scholar 
34. Murphy, G. Tissue inhibitors of metalloproteinases. Genome
Biol. 12, 233 (2011).
Article  CAS  PubMed  PubMed Central  Google Scholar 
35. Leco, K. J. et al. Spontaneous air space enlargement in the


lungs of mice lacking tissue inhibitor of metalloproteinases-3
(TIMP-3). J. Clin. Invest. 108, 817–829 (2001).
Article  CAS  PubMed  PubMed Central  Google Scholar 
36. Fata, J. E. et al. Accelerated apoptosis in the Timp-3-deficient
mammary gland. J. Clin. Invest. 108, 831–841 (2001).
Article  CAS  PubMed  PubMed Central  Google Scholar 
37. Mohammed, F. F. et al. Abnormal TNF activity in Timp3−/−
mice leads to chronic hepatic inflammation and failure of
liver regeneration. Nature Genet. 36, 969–977 (2004).
Article  CAS  PubMed  Google Scholar 
38. Whittaker, M., Floyd, C. D., Brown, P. & Gearing, A. J. Design
and therapeutic application of matrix metalloproteinase
inhibitors. Chem. Rev. 99, 2735–2776 (1999).
Article  CAS  PubMed  Google Scholar 
39. Verma, R. P. Hydroxamic acids as matrix metalloproteinase
inhibitors. EXS 103, 137–176 (2012).
CAS  PubMed  Google Scholar 
40. Macaulay, V. M. et al. Phase I study of intrapleural batimastat
(BB-94), a matrix metalloproteinase inhibitor, in the
treatment of malignant pleural effusions. Clin. Cancer Res. 5,
513–520 (1999).
CAS  PubMed  Google Scholar 
41. Acharya, M. R., Venitz, J., Figg, W. D. & Sparreboom, A.
Chemically modified tetracyclines as inhibitors of matrix
metalloproteinases. Drug Resist. Updat. 7, 195–208 (2004).
Article  PubMed  CAS  Google Scholar 
42. Eccles, S. A. et al. Control of lymphatic and hematogenous
metastasis of a rat mammary carcinoma by the matrix


metalloproteinase inhibitor batimastat (BB-94). Cancer Res.
56, 2815–2822 (1996).
CAS  PubMed  Google Scholar 
43. Sledge, G. W. et al. Effect of matrix metalloproteinase
inhibitor batimastat on breast cancer regrowth and metastasis
in athymic mice. J. Natl Cancer Inst. 87, 1546–1550 (1995).
Article  CAS  PubMed  Google Scholar 
44. Low, J. A., Johnson, M. D., Bone, E. A. & Dickson, R. B. The
matrix metalloproteinase inhibitor batimastat (BB-94) retards
human breast cancer solid tumor growth but not ascites
formation in nude mice. Clin. Cancer Res. 2, 1207–1214
(1996).
CAS  PubMed  Google Scholar 
45. Watson, S. A. et al. Inhibition of organ invasion by the matrix
metalloproteinase inhibitor batimastat (BB-94) in two human
colon carcinoma metastasis models. Cancer Res. 55, 3629–
3633 (1995).
CAS  PubMed  Google Scholar 
46. Chirivi, R. G. et al. Inhibition of the metastatic spread and
growth of B16-BL6 murine melanoma by a synthetic matrix
metalloproteinase inhibitor. Int. J. Cancer 58, 460–464
(1994).
Article  CAS  PubMed  Google Scholar 
47. Taraboletti, G. et al. Inhibition of angiogenesis and murine
hemangioma growth by batimastat, a synthetic inhibitor of
matrix metalloproteinases. J. Natl Cancer Inst. 87, 293–298
(1995).
Article  CAS  PubMed  Google Scholar 
48. Mannello, F., Tonti, G. & Papa, S. Matrix metalloproteinase
inhibitors as anticancer therapeutics. Curr. Cancer Drug


Targets 5, 285–298 (2005).
Article  CAS  PubMed  Google Scholar 
49. Vihinen, P., Ala-aho, R. & Kahari, V. M. Matrix
metalloproteinases as therapeutic targets in cancer. Curr.
Cancer Drug Targets 5, 203–220 (2005).
Article  CAS  PubMed  Google Scholar 
50. Sparano, J. A. et al. Randomized phase III trial of marimastat
versus placebo in patients with metastatic breast cancer who
have responding or stable disease after first-line
chemotherapy: Eastern Cooperative Oncology Group trial
E2196. J. Clin. Oncol. 22, 4683–4690 (2004).
Article  CAS  PubMed  Google Scholar 
51. Goffin, J. R. et al. Phase I trial of the matrix
metalloproteinase inhibitor marimastat combined with
carboplatin and paclitaxel in patients with advanced non-
small cell lung cancer. Clin. Cancer Res. 11, 3417–3424
(2005).
Article  CAS  PubMed  Google Scholar 
52. Fingleton, B. MMPs as therapeutic targets — still a viable
option? Semin. Cell Dev. Biol. 19, 61–68 (2008).
Article  CAS  PubMed  Google Scholar 
53. Fingleton, B. Matrix metalloproteinases: roles in cancer and
metastasis. Front. Biosci. 11, 479–491 (2006).
Article  CAS  PubMed  Google Scholar 
54. Kruger, A., Kates, R. E. & Edwards, D. R. Avoiding spam in
the proteolytic internet: future strategies for anti-metastatic
MMP inhibition. Biochim. Biophys. Acta 1803, 95–102 (2010).
Article  PubMed  CAS  Google Scholar 


55. Eatock, M. et al. A dose-finding and pharmacokinetic study of
the matrix metalloproteinase inhibitor MMI270 (previously
termed CGS27023A) with 5-FU and folinic acid. Cancer
Chemother. Pharmacol. 55, 39–46 (2005).
Article  CAS  PubMed  Google Scholar 
56. Hoekstra, R., Eskens, F. A. & Verweij, J. Matrix
metalloproteinase inhibitors: current developments and future
perspectives. Oncol. 6, 415–427 (2001).
CAS  Google Scholar 
57. Close, D. R. Matrix metalloproteinase inhibitors in rheumatic
diseases. Ann. Rheum. Dis. 60, iii62–iii67 (2001).
CAS  PubMed  PubMed Central  Google Scholar 
58. Li, J., et al. Synthesis and SAR of highly selective MMP-13
inhibitors. Bioorg. Med. Chem. Lett. 15, 4961–4966 (2005).
Article  CAS  PubMed  Google Scholar 
59. de Melo, E. B. A QSAR study of matrix metalloproteinases
type 2 (MMP-2) inhibitors with cinnamoyl pyrrolidine
derivatives. Scientia pharmaceutica 80, 265–281 (2012).
Article  PubMed  PubMed Central  CAS  Google Scholar 
60. Jacobsen, J. A., Major Jourden, J. L., Miller, M. T. & Cohen,
S. M. To bind zinc or not to bind zinc: an examination of
innovative approaches to improved metalloproteinase
inhibition. Biochim. Biophys. Acta 1803, 72–94 (2010).
Article  CAS  PubMed  Google Scholar 
61. Naglich, J. G. et al. Inhibition of angiogenesis and metastasis
in two murine models by the matrix metalloproteinase
inhibitor, BMS-275291. Cancer Res. 61, 8480–8485 (2001).
CAS  PubMed  Google Scholar 


62. Miller, K. D. et al. A randomized phase II feasibility trial of
BMS-275291 in patients with early stage breast cancer. Clin.
Cancer Res. 10, 1971–1975 (2004).
Article  CAS  PubMed  Google Scholar 
63. Leighl, N. B. et al. Randomized phase III study of matrix
metalloproteinase inhibitor BMS-275291 in combination with
paclitaxel and carboplatin in advanced non-small-cell lung
cancer: National Cancer Institute of Canada-Clinical Trials
Group Study BR.18. J. Clin. Oncol. 23, 2831–2839 (2005).
Article  CAS  PubMed  Google Scholar 
64. Lutz, J. et al. Inhibition of matrix metalloproteinases during
chronic allograft nephropathy in rats. Transplantation 79,
655–661 (2005).
Article  CAS  PubMed  Google Scholar 
65. Lee, M. et al. Synthesis of chiral 2-(4-
phenoxyphenylsulfonylmethyl) thiiranes as selective
gelatinase inhibitors. Org. Lett. 7, 4463–4465 (2005).
Article  CAS  PubMed  Google Scholar 
66. Ikejiri, M. et al. Potent mechanism-based inhibitors for matrix
metalloproteinases. J. Biol. Chem. 280, 33992–34002 (2005).
Article  CAS  PubMed  Google Scholar 
67. Ikejiri, M. et al. Design, synthesis, and evaluation of a
mechanism-based inhibitor for gelatinase A. J. Org. Chem. 70,
5709–5712 (2005).
Article  CAS  PubMed  Google Scholar 
68. Grams, F. et al. Pyrimidine-2,4,6-triones: a new effective and
selective class of matrix metalloproteinase inhibitors. Biol.
Chem. 382, 1277–1285 (2001).
Article  CAS  PubMed  Google Scholar 


69. Lein, M. et al. The new synthetic matrix metalloproteinase
inhibitor (Roche 28–2653) reduces tumor growth and
prolongs survival in a prostate cancer standard rat model.
Oncogene 21, 2089–2096 (2002).
Article  CAS  PubMed  Google Scholar 
70. Abramjuk, C. et al. Matrix metalloproteinase inhibitor Ro 28–
2653 in combination with estramustine: tumor-reducing
effects on hormone-sensitive prostate cancer in rats.
Anticancer Drugs 16, 855–861 (2005).
Article  CAS  PubMed  Google Scholar 
71. Kilian, M. et al. Matrix metalloproteinase inhibitor RO 28–
2653 decreases liver metastasis by reduction of MMP-2 and
MMP-9 concentration in BOP-induced ductal pancreatic
cancer in Syrian Hamsters: inhibition of matrix
metalloproteinases in pancreatic cancer. Prostaglandins Leukot.
Essent. Fatty Acids 75, 429–434 (2006).
Article  CAS  PubMed  Google Scholar 
72. Maquoi, E. et al. Anti-invasive, antitumoral, and
antiangiogenic efficacy of a pyrimidine-2,4,6-trione
derivative, an orally active and selective matrix
metalloproteinases inhibitor. Clin. Cancer Res. 10, 4038–4047
(2004).
Article  CAS  PubMed  Google Scholar 
73. De Savi, C. et al. Hydantoin based inhibitors of MMP13 —
discovery of AZD6605. Bioorg. Med. Chem. Lett. 23, 4705–
4712 (2013).
Article  CAS  PubMed  Google Scholar 
74. Hu, Y. et al. Potent, selective, and orally bioavailable matrix
metalloproteinase-13 inhibitors for the treatment of
osteoarthritis. Bioorg. Med. Chem. 13, 6629–6644 (2005).
Article  CAS  PubMed  Google Scholar 


75. Li, J. et al. Synthesis and SAR of highly selective MMP-13
inhibitors. Bioorg. Med. Chem. Lett. 15, 4961–4966 (2005).
Article  CAS  PubMed  Google Scholar 
76. Wu, J. et al. Identification of potent and selective MMP-13
inhibitors. Bioorg. Med. Chem. Lett. 15, 4105–4109 (2005).
Article  CAS  PubMed  Google Scholar 
77. Dive, V. et al. Phosphinic peptides as zinc metalloproteinase
inhibitors. Cell. Mol. Life Sci. 61, 2010–2019 (2004).
Article  CAS  PubMed  Google Scholar 
78. Reiter, L. A. et al. Phosphinic acid-based MMP-13 inhibitors
that spare MMP-1 and MMP-3. Bioorg. Med. Chem. Lett. 13,
2331–2336 (2003).
Article  CAS  PubMed  Google Scholar 
79. Dive, V. et al. Dosing and scheduling influence the antitumor
efficacy of a phosphinic peptide inhibitor of matrix
metalloproteinases. Int. J. Cancer 113, 775–781 (2005).
Article  CAS  PubMed  Google Scholar 
80. Sorsa, T. et al. Matrix metalloproteinases: contribution to
pathogenesis, diagnosis and treatment of periodontal
inflammation. Ann. Med. 38, 306–321 (2006).
Article  CAS  PubMed  Google Scholar 
81. Rudek, M. A. et al. Phase I clinical trial of oral COL-3, a
matrix metalloproteinase inhibitor, in patients with refractory
metastatic cancer. J. Clin. Oncol. 19, 584–592 (2001).
Article  CAS  PubMed  Google Scholar 
82. Schechter, I. & Berger, A. On the active site of proteases. 3.
Mapping the active site of papain; specific peptide inhibitors
of papain. Biochem. Biophys. Res. Commun. 32, 898–902


(1968).
Article  CAS  PubMed  Google Scholar 
83. Aureli, L. et al. Structural bases for substrate and inhibitor
recognition by matrix metalloproteinases. Curr. Med. Chem.
15, 2192–2222 (2008).
Article  CAS  PubMed  Google Scholar 
84. Park, H. I. et al. The intermediate S1′ pocket of the
endometase/matrilysin-2 active site revealed by enzyme
inhibition kinetic studies, protein sequence analyses, and
homology modeling. J. Biol. Chem. 278, 51646–51653
(2003).
Article  CAS  PubMed  Google Scholar 
85. Gupta, S. P. & Patil, V. M. Specificity of binding with matrix
metalloproteinases. EXS 103, 35–56 (2012).
CAS  PubMed  Google Scholar 
86. Gupta, S. P. Matrix metalloproteinase inhibitors: specificity of
binding and structure-activity relationships. EXS 103, v–vi
(2012).
PubMed  Google Scholar 
87. Gege, C. et al. Discovery and evaluation of a non-Zn
chelating, selective matrix metalloproteinase 13 (MMP-13)
inhibitor for potential intra-articular treatment of
osteoarthritis. J. Med. Chem. 55, 709–716 (2012).
Article  CAS  PubMed  Google Scholar 
88. Jungel, A. et al. Effect of the oral application of a highly
selective MMP-13 inhibitor in three different animal models
of rheumatoid arthritis. Ann. Rheum. Dis. 69, 898–902 (2010).
Article  CAS  PubMed  Google Scholar 


89. Schnute, M. E. et al. Discovery of (pyridin-4-yl)-2H-tetrazole
as a novel scaffold to identify highly selective matrix
metalloproteinase-13 inhibitors for the treatment of
osteoarthritis. Bioorg. Med. Chem. Lett. 20, 576–580 (2010).
Article  CAS  PubMed  Google Scholar 
90. Fabre, B. et al. An integrated computational and experimental
approach to gaining selectivity for MMP-2 within the
gelatinase subfamily. Chembiochem. 15, 399–412 (2014).
Article  CAS  PubMed  Google Scholar 
91. Roth, J. et al. Identification of novel, exosite-binding matrix
metalloproteinase-13 inhibitor scaffolds. Bioorg. Med. Chem.
Lett. 21, 7180–7184 (2011).
Article  CAS  PubMed  PubMed Central  Google Scholar 
92. Udi, Y. et al. Unraveling hidden regulatory sites in
structurally homologous metalloproteases. J. Mol. Biol. 425,
2330–2346 (2013).
Article  CAS  PubMed  Google Scholar 
93. Ndinguri, M. W., Bhowmick, M., Tokmina-Roszyk, D.,
Robichaud, T. K. & Fields, G. B. Peptide-based selective
inhibitors of matrix metalloproteinase-mediated activities.
Molecules 17, 14230–14248 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
94. Koivunen, E. et al. Tumor targeting with a selective gelatinase
inhibitor. Nature Biotech. 17, 768–774 (1999).
Article  CAS  Google Scholar 
95. Suojanen, J., Salo, T., Koivunen, E., Sorsa, T. & Pirila, E. A
novel and selective membrane type-1 matrix
metalloproteinase (MT1-MMP) inhibitor reduces cancer cell
motility and tumor growth. Cancer Biol. Ther. 8, 2362–2370
(2009).


Article  CAS  PubMed  Google Scholar 
96. Devy, L. & Dransfield, D. T. New strategies for the next
generation of matrix-metalloproteinase inhibitors: selectively
targeting membrane-anchored MMPs with therapeutic
antibodies. Biochem. Res. Int. 2011, 191670 (2011).
Article  PubMed  CAS  Google Scholar 
97. Hoet, R. M. et al. Generation of high-affinity human
antibodies by combining donor-derived and synthetic
complementarity-determining-region diversity. Nature Biotech.
23, 344–348 (2005).
Article  CAS  Google Scholar 
98. Devy, L. et al. Selective inhibition of matrix
metalloproteinase-14 blocks tumor growth, invasion, and
angiogenesis. Cancer Res. 69, 1517–1526 (2009).
Article  CAS  PubMed  Google Scholar 
99. Ingvarsen, S. et al. Targeting a single function of the
multifunctional matrix metalloprotease MT1-MMP: impact on
lymphangiogenesis. J. Biol. Chem. 288, 10195–10204 (2013).
Article  CAS  PubMed  PubMed Central  Google Scholar 
100. Kaimal, R. et al. Selective blockade of matrix
metalloprotease-14 with a monoclonal antibody abrogates
invasion, angiogenesis, and tumor growth in ovarian cancer.
Cancer Res. 73, 2457–2467 (2013).
Article  CAS  PubMed  PubMed Central  Google Scholar 
101. Basu, B. et al. Inhibition of MT1-MMP activity using
functional antibody fragments selected against its hemopexin
domain. Int. J. Biochem. Cell Biol. 44, 393–403 (2012).
Article  CAS  PubMed  Google Scholar 
102. Hu, J., Van den Steen, P. E., Houde, M., Ilenchuk, T. T. &


Opdenakker, G. Inhibitors of gelatinase B/matrix
metalloproteinase-9 activity comparison of a peptidomimetic
and polyhistidine with single-chain derivatives of a
neutralizing monoclonal antibody. Biochem. Pharmacol. 67,
1001–1009 (2004).
Article  CAS  PubMed  Google Scholar 
103. Martens, E. et al. A monoclonal antibody inhibits gelatinase
B/MMP-9 by selective binding to part of the catalytic domain
and not to the fibronectin or zinc binding domains. Biochim.
Biophys. Acta 1770, 178–186 (2007).
Article  CAS  PubMed  Google Scholar 
104. Shiryaev, S. A. et al. A monoclonal antibody interferes with
TIMP-2 binding and incapacitates the MMP-2-activating
function of multifunctional, pro-tumorigenic MMP-14/MT1-
MMP. Oncogenesis 2, e80 (2013).
Article  CAS  PubMed  PubMed Central  Google Scholar 
105. Sela-Passwell, N. et al. Antibodies targeting the catalytic zinc
complex of activated matrix metalloproteinases show
therapeutic potential. Nature Med. 18, 143–147 (2012).
Article  CAS  Google Scholar 
106. Naito, S. et al. Development of a neutralizing antibody
specific for the active form of matrix metalloproteinase-13.
Biochemistry 51, 8877–8884 (2012).
Article  CAS  PubMed  Google Scholar 
107. Bu, Z. et al. SZ-117, a monoclonal antibody against matrix
metalloproteinase-2 inhibits tumor cell-mediated
angiogenesis. Hybridoma 31, 63–67 (2012).
Article  CAS  PubMed  Google Scholar 
108. Tchetverikov, I. et al. Active MMPs captured by alpha 2
macroglobulin as a marker of disease activity in rheumatoid


arthritis. Clin. Exp. Rheumatol 21, 711–718 (2003).
CAS  PubMed  Google Scholar 
109. Etique, N., Verzeaux, L., Dedieu, S. & Emonard, H. LRP-1: a
checkpoint for the extracellular matrix proteolysis. BioMed
Res. Int. 2013, 152163 (2013).
Article  PubMed  PubMed Central  CAS  Google Scholar 
110. Birkenmeier, G. et al. Polymyxin B-conjugated α2-
macroglobulin as an adjunctive therapy to sepsis: modes of
action and impact on lethality. J. Pharmacol. Exp. Ther. 318,
762–771 (2006).
Article  CAS  PubMed  Google Scholar 
111. Webb, D. J. & Gonias, S. L. A modified human alpha 2-
macroglobulin derivative that binds tumor necrosis factor-
alpha and interleukin-1 beta with high affinity in vitro and
reverses lipopolysaccharide toxicity in vivo in mice. Lab.
Invest. 78, 939–948 (1998).
CAS  PubMed  Google Scholar 
112. Amour, A. et al. The in vitro activity of ADAM-10 is inhibited
by TIMP-1 and TIMP-3. FEBS Lett. 473, 275–279 (2000).
Article  CAS  PubMed  Google Scholar 
113. Smookler, D. S. et al. Tissue inhibitor of metalloproteinase 3
regulates TNF-dependent systemic inflammation. J. Immunol.
176, 721–725 (2006).
Article  CAS  PubMed  Google Scholar 
114. Vanhoutte, D. & Heymans, S. TIMPs and cardiac remodeling:
'Embracing the MMP-independent-side of the family'. J. Mol.
Cell Cardiol. 48, 445–453 (2010).
Article  CAS  PubMed  Google Scholar 


115. Moore, C. S. & Crocker, S. J. An alternate perspective on the
roles of TIMPs and MMPs in pathology. Am. J. Pathol. 180,
12–16 (2012).
Article  CAS  PubMed  Google Scholar 
116. Stetler-Stevenson, W. G. Tissue inhibitors of
metalloproteinases in cell signaling: metalloproteinase-
independent biological activities. Sci. Signal. 1, re6 (2008).
Article  PubMed  PubMed Central  Google Scholar 
117. Seo, D. W. et al. TIMP-2 mediated inhibition of angiogenesis:
an MMP-independent mechanism. Cell 114, 171–180 (2003).
Article  CAS  PubMed  Google Scholar 
118. Stetler-Stevenson, W. G. & Seo, D. W. TIMP-2: an endogenous
inhibitor of angiogenesis. Trends Mol. Med. 11, 97–103
(2005).
Article  CAS  PubMed  Google Scholar 
119. Nieuwesteeg, M. A., Walsh, L. A., Fox, M. A. & Damjanovski,
S. Domain specific overexpression of TIMP-2 and TIMP-3
reveals MMP-independent functions of TIMPs during Xenopus
laevis development. Biochem. Cell Biol. 90, 585–595 (2012).
Article  CAS  PubMed  Google Scholar 
120. Butler, G. S. et al. The TIMP2 membrane type 1
metalloproteinase “receptor” regulates the concentration and
efficient activation of progelatinase A. A kinetic study. J. Biol.
Chem. 273, 871–880 (1998).
Article  CAS  PubMed  Google Scholar 
121. Hu, J., Van den Steen, P. E., Sang, Q. X. & Opdenakker, G.
Matrix metalloproteinase inhibitors as therapy for
inflammatory and vascular diseases. Nature Rev. Drug Discov.
6, 480–498 (2007).


Article  CAS  Google Scholar 
122. Qiu, Z., Hu, J., Van den Steen, P. E. & Opdenakker, G.
Targeting matrix metalloproteinases in acute inflammatory
shock syndromes. Comb. Chem. High Throughput Screen. 15,
555–570 (2012).
Article  CAS  PubMed  Google Scholar 
123. Vandenbroucke, R. E., Dejonckheere, E. & Libert, C. A
therapeutic role for matrix metalloproteinase inhibitors in
lung diseases? Eur. Respir. J. 38, 1200–1214 (2011).
Article  CAS  PubMed  Google Scholar 
124. Dejonckheere, E., Vandenbroucke, R. E. & Libert, C. Matrix
metalloproteinases as drug targets in ischemia/reperfusion
injury. Drug Discov. Today 16, 762–778 (2011).
CAS  PubMed  Google Scholar 
125. Newby, A. C. Matrix metalloproteinase inhibition therapy for
vascular diseases. Vascul. Pharmacol. 56, 232–244 (2012).
Article  CAS  PubMed  Google Scholar 
126. Yabluchanskiy, A., Ma, Y., Iyer, R. P., Hall, M. E. & Lindsey,
M. L. Matrix metalloproteinase-9: many shades of function in
cardiovascular disease. Physiology 28, 391–403 (2013).
Article  CAS  PubMed  PubMed Central  Google Scholar 
127. Halade, G. V., Jin, Y. F. & Lindsey, M. L. Matrix
metalloproteinase (MMP)-9: a proximal biomarker for cardiac
remodeling and a distal biomarker for inflammation.
Pharmacol. Ther. 139, 32–40 (2013).
Article  CAS  PubMed  PubMed Central  Google Scholar 
128. Nissinen, L. & Kahari, V. M. Matrix metalloproteinases in
inflammation. Biochim. Biophys. Acta 1840, 2571–2580
(2014).


Article  CAS  PubMed  Google Scholar 
129. Angus, D. C. & van der Poll, T. Severe sepsis and septic shock.
N. Engl. J. Med. 369, 2063 (2013).
Article  CAS  PubMed  Google Scholar 
130. Marti-Carvajal, A. J., Sola, I., Gluud, C., Lathyris, D. &
Cardona, A. F. Human recombinant protein C for severe
sepsis and septic shock in adult and paediatric patients.
Cochrane Database Syst. Rev. 12, CD004388 (2012).
PubMed  Google Scholar 
131. Deutschman, C. S. Steroid responses in sepsis: some novel
thinking that may provide new insight. Crit. Care 17, 147
(2013).
Article  PubMed  PubMed Central  Google Scholar 
132. Seok, J. et al. Genomic responses in mouse models poorly
mimic human inflammatory diseases. Proc. Natl Acad. Sci.
USA 110, 3507–3512 (2013).
Article  CAS  PubMed  PubMed Central  Google Scholar 
133. Dejager, L., Pinheiro, I., Dejonckheere, E. & Libert, C. Cecal
ligation and puncture: the gold standard model for
polymicrobial sepsis? Trends Microbiol. 19, 198–208 (2011).
Article  CAS  PubMed  Google Scholar 
134. Okamoto, T. et al. Activation of human matrix
metalloproteinases by various bacterial proteinases. J. Biol.
Chem. 272, 6059–6066 (1997).
Article  CAS  PubMed  Google Scholar 
135. Elkington, P. T., Green, J. A. & Friedland, J. S. Analysis of
matrix metalloproteinase secretion by macrophages. Methods
Mol. Biol. 531, 253–265 (2009).


Article  CAS  PubMed  Google Scholar 
136. Lalu, M. M., Cena, J., Chowdhury, R., Lam, A. & Schulz, R.
Matrix metalloproteinases contribute to endotoxin and
interleukin-1β induced vascular dysfunction. Br. J. Pharmacol.
149, 31–42 (2006).
Article  CAS  PubMed  PubMed Central  Google Scholar 
137. Dubois, B. et al. Gelatinase B deficiency protects against
endotoxin shock. Eur. J. Immunol. 32, 2163–2171 (2002).
Article  CAS  PubMed  Google Scholar 
138. Barichello, T. et al. Inhibition of matrix metalloproteinases-2
and -9 prevents cognitive impairment induced by
pneumococcal meningitis in Wistar rats. Exp. Biol. Med. 239,
225–231 (2014).
Article  CAS  Google Scholar 
139. Pagenstecher, A., Stalder, A. K., Kincaid, C. L., Volk, B. &
Campbell, I. L. Regulation of matrix metalloproteinases and
their inhibitor genes in lipopolysaccharide-induced
endotoxemia in mice. Am. J. Pathol. 157, 197–210 (2000).
Article  CAS  PubMed  PubMed Central  Google Scholar 
140. Rahman, M. et al. Metalloproteinases regulate CD40L
shedding from platelets and pulmonary recruitment of
neutrophils in abdominal sepsis. Inflamm. Res. 61, 571–579
(2012).
Article  CAS  PubMed  Google Scholar 
141. Chen, J. et al. Biodistribution of radiolabeled [(3)H] CMT-3 in
rats. Curr. Med. Chem. 8, 253–256 (2001).
Article  CAS  PubMed  Google Scholar 
142. Liu, Y. et al. The lipophilicity, pharmacokinetics, and cellular
uptake of different chemically-modified tetracyclines (CMTs).


Curr. Med. Chem. 8, 243–252 (2001).
Article  CAS  PubMed  Google Scholar 
143. Steinberg, J. et al. Metalloproteinase inhibition reduces lung
injury and improves survival after cecal ligation and puncture
in rats. J. Surg. Res. 111, 185–195 (2003).
Article  CAS  PubMed  Google Scholar 
144. Vandooren, J., Van den Steen, P. E. & Opdenakker, G.
Biochemistry and molecular biology of gelatinase B or matrix
metalloproteinase-9 (MMP-9): the next decade. Crit. Rev.
Biochem. Mol. Biol. 48, 222–272 (2013).
Article  CAS  PubMed  Google Scholar 
145. Muhl, D. et al. Dynamic changes of matrix metalloproteinases
and their tissue inhibitors in severe sepsis. J. Crit. Care 26,
550–555 (2011).
Article  PubMed  CAS  Google Scholar 
146. Maitra, S. R., Jacob, A., Zhou, M. & Wang, P. Modulation of
matrix metalloproteinase-9 and tissue inhibitor of matrix
metalloproteinase-1 in sepsis. Int. J. Clin. Exp. Med. 3, 180–
185 (2010).
CAS  PubMed  PubMed Central  Google Scholar 
147. Hu, J., Van den Steen, P. E., Dillen, C. & Opdenakker, G.
Targeting neutrophil collagenase/matrix metalloproteinase-8
and gelatinase B/matrix metalloproteinase-9 with a
peptidomimetic inhibitor protects against endotoxin shock.
Biochem. Pharmacol. 70, 535–544 (2005).
Article  CAS  PubMed  Google Scholar 
148. Renckens, R. et al. Matrix metalloproteinase-9 deficiency
impairs host defense against abdominal sepsis. J. Immunol.
176, 3735–3741 (2006).


Article  CAS  PubMed  Google Scholar 
149. Dal-Pizzol, F. et al. Matrix metalloproteinase-2 and
metalloproteinase-9 activities are associated with blood-brain
barrier dysfunction in an animal model of severe sepsis. Mol.
Neurobiol. 48, 62–70 (2013).
Article  CAS  PubMed  Google Scholar 
150. Tressel, S. L. et al. A matrix metalloprotease-PAR1 system
regulates vascular integrity, systemic inflammation and death
in sepsis. EMBO Mol. Med. 3, 370–384 (2011).
Article  CAS  PubMed  PubMed Central  Google Scholar 
151. Schouten, M., Wiersinga, W. J., Levi, M. & van der Poll, T.
Inflammation, endothelium, and coagulation in sepsis. J.
Leukoc. Biol. 83, 536–545 (2008).
Article  CAS  PubMed  Google Scholar 
152. Vandenbroucke, R. E., Dejager, L. & Libert, C. The first MMP
in sepsis. EMBO Mol. Med. 3, 367–369 (2011).
Article  CAS  PubMed  PubMed Central  Google Scholar 
153. Fanjul-Fernandez, M. et al. Matrix metalloproteinase Mmp-1a
is dispensable for normal growth and fertility in mice and
promotes lung cancer progression by modulating
inflammatory responses. J. Biol. Chem. 288, 14647–14656
(2013).
Article  CAS  PubMed  PubMed Central  Google Scholar 
154. Van Lint, P. & Libert, C. Matrix metalloproteinase-8: cleavage
can be decisive. Cytokine Growth Factor Rev. 17, 217–223
(2006).
Article  CAS  PubMed  Google Scholar 
155. Dejonckheere, E., Vandenbroucke, R. E. & Libert, C. Matrix
metalloproteinase8 has a central role in inflammatory


disorders and cancer progression. Cytokine Growth Factor Rev.
22, 73–81 (2011).
Article  CAS  PubMed  Google Scholar 
156. Tester, A. M. et al. LPS responsiveness and neutrophil
chemotaxis in vivo require PMN MMP-8 activity. PLoS ONE 2,
e312 (2007).
Article  PubMed  PubMed Central  CAS  Google Scholar 
157. Lauhio, A. et al. Serum MMP-8, -9 and TIMP-1 in sepsis: high
serum levels of MMP-8 and TIMP-1 are associated with fatal
outcome in a multicentre, prospective cohort study.
Hypothetical impact of tetracyclines. Pharmacol. Res. 64,
590–594 (2011).
Article  CAS  PubMed  Google Scholar 
158. Solan, P. D. et al. A novel role for matrix metalloproteinase-8
in sepsis. Crit. Care Med. 40, 379–387 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
159. Punyadeera, C. et al. A biomarker panel to discriminate
between systemic inflammatory response syndrome and sepsis
and sepsis severity. J. Emerg. Trauma Shock 3, 26–35 (2010).
Article  PubMed  PubMed Central  Google Scholar 
160. Hoffmann, U., Brueckmann, M. & Borggrefe, M. Matrix
metalloproteinases and their inhibitors: promising novel
biomarkers in severe sepsis? Crit. Care 13, 1006 (2009).
Article  PubMed  PubMed Central  Google Scholar 
161. Vandenbroucke, R. E. et al. Matrix metalloprotease 8-
dependent extracellular matrix cleavage at the blood-CSF
barrier contributes to lethality during systemic inflammatory
diseases. J. Neurosci. 32, 9805–9816 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 


162. Gonzalez-Lopez, A. et al. MMP-8 deficiency increases TLR/
RAGE ligands S100A8 and S100A9 and exacerbates lung
inflammation during endotoxemia. PLoS ONE 7, e39940
(2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
163. Singh, A. et al. Collagenase-3 (MMP-13) deficiency protects
C57BL/6 mice from antibody-induced arthritis. Arthritis Res.
Ther. 15, R222 (2013).
Article  PubMed  PubMed Central  CAS  Google Scholar 
164. Toriseva, M. et al. MMP-13 regulates growth of wound
granulation tissue and modulates gene expression signatures
involved in inflammation, proteolysis, and cell viability. PLoS
ONE 7, e42596 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
165. Li, N. G., Tang, Y. P. & Duan, J. A. New selective inhibitors of
MMP-13 for inflammatory diseases: a patent evaluation
(W02012151158). Expert Opin. Ther. Pat. 23, 669–675
(2013).
Article  CAS  PubMed  Google Scholar 
166. Muddasani, P., Norman, J. C., Ellman, M., van Wijnen, A. J. &
Im, H. J. Basic fibroblast growth factor activates the MAPK
and NFκB pathways that converge on Elk-1 to control
production of matrix metalloproteinase-13 by human adult
articular chondrocytes. J. Biol. Chem. 282, 31409–31421
(2007).
Article  CAS  PubMed  Google Scholar 
167. Ahmad, R., Sylvester, J. & Zafarullah, M. MyD88, IRAK1 and
TRAF6 knockdown in human chondrocytes inhibits
interleukin-1-induced matrix metalloproteinase-13 gene
expression and promoter activity by impairing MAP kinase
activation. Cell Signal. 19, 2549–2557 (2007).


Article  CAS  PubMed  Google Scholar 
168. Uhlenhaut, N. H. et al. Insights into negative regulation by
the glucocorticoid receptor from genome-wide profiling of
inflammatory cistromes. Mol. Cell 49, 158–171 (2013).
Article  CAS  PubMed  Google Scholar 
169. Vandenbroucke, R. E. et al. Matrix metalloproteinase 13
modulates intestinal epithelial barrier integrity in
inflammatory diseases by activating TNF. EMBO Mol. Med. 5,
932–948 (2013).
Article  CAS  PubMed Central  Google Scholar 
170. Carrico, C. J., Meakins, J. L., Marshall, J. C., Fry, D. & Maier,
R. V. Multiple-organ-failure syndrome. Arch. Surg. 121, 196–
208 (1986).
Article  CAS  PubMed  Google Scholar 
171. Deitch, E. A. & Berg, R. Bacterial translocation from the gut: a
mechanism of infection. J. Burn Care Rehabil. 8, 475–482
(1987).
Article  CAS  PubMed  Google Scholar 
172. Gearing, A. J. et al. Matrix metalloproteinases and processing
of pro-TNF-α. J. Leukoc. Biol. 57, 774–777 (1995).
Article  CAS  PubMed  Google Scholar 
173. Chandler, S., Cossins, J., Lury, J. & Wells, G. Macrophage
metalloelastase degrades matrix and myelin proteins and
processes a tumour necrosis factor-α fusion protein. Biochem.
Biophys. Res. Commun. 228, 421–429 (1996).
Article  CAS  PubMed  Google Scholar 
174. d'Ortho, M. P. et al. Membrane-type matrix
metalloproteinases 1 and 2 exhibit broad-spectrum
proteolytic capacities comparable to many matrix


metalloproteinases. Eur. J. Biochem. 250, 751–757 (1997).
Article  CAS  PubMed  Google Scholar 
175. Tam, E. M., Morrison, C. J., Wu, Y. I., Stack, M. S. & Overall,
C. M. Membrane protease proteomics: isotope-coded affinity
tag MS identification of undescribed MT1-matrix
metalloproteinase substrates. Proc. Natl Acad. Sci. USA 101,
6917–6922 (2004).
Article  CAS  PubMed  PubMed Central  Google Scholar 
176. Becker-Pauly, C. & Rose-John, S. TNFα cleavage beyond
TACE/ADAM17: matrix metalloproteinase 13 is a potential
therapeutic target in sepsis and colitis. EMBO Mol. Med. 5,
902–904 (2013).
Article  CAS  PubMed Central  Google Scholar 
177. Marchenko, G. N. & Strongin, A. Y. MMP-28, a new human
matrix metalloproteinase with an unusual cysteine-switch
sequence is widely expressed in tumors. Gene 265, 87–93
(2001).
Article  CAS  PubMed  Google Scholar 
178. Vandenbroucke, R. E. et al. Pro-inflammatory effects of
matrix metalloproteinase 7 in acute inflammation. Mucosal
Immunol. 7, 579–588 (2014).
Article  CAS  PubMed  Google Scholar 
179. Gaddnas, F. P. et al. Matrix-metalloproteinase-2, -8 and -9 in
serum and skin blister fluid in patients with severe sepsis.
Crit. Care 14, R49 (2010).
Article  PubMed  PubMed Central  Google Scholar 
180. MacDonald, T. T., Monteleone, I., Fantini, M. C. &
Monteleone, G. Regulation of homeostasis and inflammation
in the intestine. Gastroenterology 140, 1768–1775 (2011).


Article  CAS  PubMed  Google Scholar 
181. Giuffrida, P., Biancheri, P. & Macdonald, T. T. Proteases and
small intestinal barrier function in health and disease. Curr.
Opin. Gastroenterol. 30, 147–153 (2014).
Article  CAS  PubMed  Google Scholar 
182. Medina, C. & Radomski, M. W. Role of matrix
metalloproteinases in intestinal inflammation. J. Pharmacol.
Exp. Ther. 318, 933–938 (2006).
Article  CAS  PubMed  Google Scholar 
183. Pedersen, J., Coskun, M., Soendergaard, C., Salem, M. &
Nielsen, O. H. Inflammatory pathways of importance for
management of inflammatory bowel disease. World J.
Gastroenterol. 20, 64–77 (2014).
Article  PubMed  PubMed Central  CAS  Google Scholar 
184. Billiet, T., Rutgeerts, P., Ferrante, M., Van Assche, G. &
Vermeire, S. Targeting TNF-α for the treatment of
inflammatory bowel disease. Expert Opin. Biol. Ther. 14, 75–
101 (2014).
Article  CAS  PubMed  Google Scholar 
185. Podolsky, D. K. Beyond tumor necrosis factor: next-generation
biologic therapy for inflammatory bowel disease. Dig. Dis. 27,
366–369 (2009).
Article  PubMed  Google Scholar 
186. Morgan, A. R. et al. Genetic variations in matrix
metalloproteinases may be associated with increased risk of
ulcerative colitis. Hum. Immunol. 72, 1117–1127 (2011).
Article  CAS  PubMed  Google Scholar 
187. Sykes, A. P. et al. The effect of an inhibitor of matrix
metalloproteinases on colonic inflammation in a


trinitrobenzenesulphonic acid rat model of inflammatory
bowel disease. Aliment. Pharmacol. Ther. 13, 1535–1542
(1999).
Article  CAS  PubMed  Google Scholar 
188. Di Sebastiano, P. et al. Beneficial effects of batimastat
(BB-94), a matrix metalloproteinase inhibitor, in rat
experimental colitis. Digestion 63, 234–239 (2001).
Article  CAS  PubMed  Google Scholar 
189. Gingras, D. et al. Neovastat — a novel antiangiogenic drug for
cancer therapy. Anticancer Drugs 14, 91–96 (2003).
Article  CAS  PubMed  Google Scholar 
190. Gingras, D., Batist, G. & Beliveau, R. AE-941 (neovastat): a
novel multifunctional antiangiogenic compound. Expert Rev.
Anticancer Ther. 1, 341–347 (2001).
Article  CAS  PubMed  Google Scholar 
191. Mao, J. W., He, X. M., Tang, H. Y. & Wang, Y. D. Protective
role of metalloproteinase inhibitor (AE-941) on ulcerative
colitis in rats. World J. Gastroenterol. 18, 7063–7069 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
192. Huang, T. Y. et al. Minocycline attenuates experimental
colitis in mice by blocking expression of inducible nitric oxide
synthase and matrix metalloproteinases. Toxicol. Appl.
Pharmacol. 237, 69–82 (2009).
Article  CAS  PubMed  Google Scholar 
193. Wang, Y. D. & Wang, W. Protective effect of ilomastat on
trinitrobenzenesulfonic acid-induced ulcerative colitis in rats.
World J. Gastroenterol. 14, 5683–5688 (2008).
Article  CAS  PubMed  PubMed Central  Google Scholar 


194. Naito, Y. et al. An orally active matrix metalloproteinase
inhibitor, ONO-4817, reduces dextran sulfate sodium-induced
colitis in mice. Inflamm. Res. 53, 462–468 (2004).
Article  CAS  PubMed  Google Scholar 
195. Medina, C. et al. Increased activity and expression of matrix
metalloproteinase-9 in a rat model of distal colitis. Am. J.
Physiol. Gastrointest. Liver Physiol. 284, G116–G122 (2003).
Article  CAS  PubMed  Google Scholar 
196. Rath, T. et al. Cellular sources of MMP-7, MMP-13 and
MMP-28 in ulcerative colitis. Scand. J. Gastroenterol. 45,
1186–1196 (2010).
Article  CAS  PubMed  Google Scholar 
197. von Lampe, B., Barthel, B., Coupland, S. E., Riecken, E. O. &
Rosewicz, S. Differential expression of matrix
metalloproteinases and their tissue inhibitors in colon mucosa
of patients with inflammatory bowel disease. Gut 47, 63–73
(2000).
Article  CAS  PubMed  PubMed Central  Google Scholar 
198. Lakatos, G. et al. The impact of matrix metalloproteinases and
their tissue inhibitors in inflammatory bowel diseases. Dig.
Dis. 30, 289–295 (2012).
Article  PubMed  Google Scholar 
199. Koelink, P. J. et al. Collagen degradation and neutrophilic
infiltration: a vicious circle in inflammatory bowel disease.
Gut 63, 578–587 (2014).
Article  CAS  PubMed  Google Scholar 
200. Santana, A. et al. Attenuation of dextran sodium sulphate
induced colitis in matrix metalloproteinase-9 deficient mice.
World J. Gastroenterol. 12, 6464–6472 (2006).


Article  CAS  PubMed  PubMed Central  Google Scholar 
201. Castaneda, F. E. et al. Targeted deletion of metalloproteinase
9 attenuates experimental colitis in mice: central role of
epithelial-derived MMP. Gastroenterology 129, 1991–2008
(2005).
Article  CAS  PubMed  Google Scholar 
202. Liu, H. et al. Constitutive expression of MMP9 in intestinal
epithelium worsens murine acute colitis and is associated
with increased levels of proinflammatory cytokine Kc. Am. J.
Physiol. Gastrointest. Liver Physiol. 304, G793–G803 (2013).
Article  CAS  PubMed  Google Scholar 
203. Ishida, K. et al. Role of chymase-dependent matrix
metalloproteinase-9 activation in mice with dextran sodium
sulfate-induced colitis. J. Pharmacol. Exp. Ther. 324, 422–426
(2008).
Article  CAS  PubMed  Google Scholar 
204. Rodrigues, D. M. et al. Matrix metalloproteinase 9 contributes
to gut microbe homeostasis in a model of infectious colitis.
BMC Microbiol. 12, 105 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
205. Garg, P. et al. Selective ablation of matrix
metalloproteinase-2 exacerbates experimental colitis:
contrasting role of gelatinases in the pathogenesis of colitis. J.
Immunol. 177, 4103–4112 (2006).
Article  CAS  PubMed  Google Scholar 
206. Garg, P. et al. Matrix metalloproteinase-9-mediated tissue
injury overrides the protective effect of matrix
metalloproteinase-2 during colitis. Am. J. Physiol. Gastrointest
Liver Physiol. 296, G175–G184 (2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 


207. Wang, Y. D., Tan, X. Y. & Zhang, K. Correlation of plasma
MMP-1 and TIMP-1 levels and the colonic mucosa expressions
in patients with ulcerative colitis. Mediators Inflamm. 2009,
275072 (2009).
Article  PubMed  PubMed Central  CAS  Google Scholar 
208. Stallmach, A. et al. Comparable expression of matrix
metalloproteinases 1 and 2 in pouchitis and ulcerative colitis.
Gut 47, 415–422 (2000).
Article  CAS  PubMed  PubMed Central  Google Scholar 
209. Wang, Y. D. & Yan, P. Y. Expression of matrix
metalloproteinase-1 and tissue inhibitor of
metalloproteinase-1 in ulcerative colitis. World J.
Gastroenterol. 12, 6050–6053 (2006).
Article  CAS  PubMed  PubMed Central  Google Scholar 
210. Wang, Y. D. & Mao, J. W. Expression of matrix
metalloproteinase-1 and tumor necrosis factor-α in ulcerative
colitis. World J. Gastroenterol. 13, 5926–5932 (2007).
Article  CAS  PubMed  PubMed Central  Google Scholar 
211. Gordon, J. N. et al. Matrix metalloproteinase-3 production by
gut IgG plasma cells in chronic inflammatory bowel disease.
Inflamm. Bowel Dis. 14, 195–203 (2008).
Article  PubMed  Google Scholar 
212. Meijer, M. J. et al. Increased mucosal matrix
metalloproteinase-1, -2, -3 and -9 activity in patients with
inflammatory bowel disease and the relation with Crohn's
disease phenotype. Dig. Liver Dis. 39, 733–739 (2007).
Article  CAS  PubMed  Google Scholar 
213. Kruidenier, L., MacDonald, T. T., Collins, J. E., Pender, S. L. &
Sanderson, I. R. Myofibroblast matrix metalloproteinases
activate the neutrophil chemoattractant CXCL7 from


intestinal epithelial cells. Gastroenterology 130, 127–136
(2006).
Article  CAS  PubMed  Google Scholar 
214. Kobayashi, K. et al. Therapeutic implications of the specific
inhibition of causative matrix metalloproteinases in
experimental colitis induced by dextran sulphate sodium. J.
Pathol. 209, 376–383 (2006).
Article  CAS  PubMed  Google Scholar 
215. Koller, F. L. et al. Lack of MMP10 exacerbates experimental
colitis and promotes development of inflammation-associated
colonic dysplasia. Lab. Invest. 92, 1749–1759 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
216. Hackam, D. J., Afrazi, A., Good, M. & Sodhi, C. P. Innate
immune signaling in the pathogenesis of necrotizing
enterocolitis. Clin. Dev. Immunol. 2013, 475415 (2013).
Article  PubMed  PubMed Central  CAS  Google Scholar 
217. Pender, S. L. et al. Matrix metalloproteinases in necrotising
enterocolitis. Pediatr. Res. 54, 160–164 (2003).
Article  CAS  PubMed  Google Scholar 
218. Bister, V. et al. Matrilysins-1 and -2 (MMP-7 and -26) and
metalloelastase (MMP-12), unlike MMP-19, are up-regulated
in necrotizing enterocolitis. J. Pediatr. Gastroenterol. Nutr. 40,
60–66 (2005).
Article  CAS  PubMed  Google Scholar 
219. Gunther, U. et al. Fibrogenesis and fibrolysis in collagenous
colitis. Patterns of procollagen types I and IV, matrix-
metalloproteinase-1 and -13, and TIMP-1 gene expression.
Am. J. Pathol. 155, 493–503 (1999).
Article  CAS  PubMed  PubMed Central  Google Scholar 


220. Altadill, A. et al. Comparative analysis of the expression of
metalloproteases and their inhibitors in resected crohn's
disease and complicated diverticular disease. Inflamm. Bowel
Dis. 18, 120–130 (2012).
Article  PubMed  Google Scholar 
221. Rosemar, A., Ivarsson, M. L., Borjesson, L. & Holmdahl, L.
Increased concentration of tissue-degrading matrix
metalloproteinases and their inhibitor in complicated
diverticular disease. Scand. J. Gastroenterol. 42, 215–220
(2007).
Article  CAS  PubMed  Google Scholar 
222. Morancho, A., Rosell, A., Garcia-Bonilla, L. & Montaner, J.
Metalloproteinase and stroke infarct size: role for anti-
inflammatory treatment? Ann. NY Acad. Sci. 1207, 123–133
(2010).
Article  CAS  PubMed  Google Scholar 
223. Romi, F., Helgeland, G. & Gilhus, N. E. Serum levels of matrix
metalloproteinases: implications in clinical neurology. Eur.
Neurol. 67, 121–128 (2012).
Article  CAS  PubMed  Google Scholar 
224. Seo, J. H. et al. Neurovascular matrix metalloproteinases and
the blood–brain barrier. Curr. Pharm. Design 18, 3645–3648
(2012).
Article  CAS  Google Scholar 
225. Florczak-Rzepka, M., Grond-Ginsbach, C., Montaner, J. &
Steiner, T. Matrix metalloproteinases in human spontaneous
intracerebral hemorrhage: an update. Cerebrovasc. Dis. 34,
249–262 (2012).
Article  CAS  PubMed  Google Scholar 
226. Yamashita, T. & Abe, K. Therapeutic approaches to vascular


protection in ischemic stroke. Acta Med. Okayama 65, 219–
223 (2011).
CAS  PubMed  Google Scholar 
227. Mroczko, B., Groblewska, M. & Barcikowska, M. The role of
matrix metalloproteinases and tissue inhibitors of
metalloproteinases in the pathophysiology of
neurodegeneration: a literature study. J. Alzheimers Dis. 37,
273–283 (2013).
Article  CAS  PubMed  Google Scholar 
228. Elgebaly, M. M. et al. Vascular protection in diabetic stroke:
role of matrix metalloprotease-dependent vascular
remodeling. J. Cereb. Blood Flow Metab. 30, 1928–1938
(2010).
Article  CAS  PubMed  PubMed Central  Google Scholar 
229. Kurzepa, J., Kurzepa, J., Golab, P., Czerska, S. & Bielewicz, J.
The significance of matrix metalloproteinase (MMP)-2 and
MMP-9 in the ischemic stroke. Int. J. Neurosci. http://
dx.doi.org10.3109/00207454.2013.872102 (2014).
230. Chaturvedi, M. & Kaczmarek, L. MMP-9 inhibition: a
therapeutic strategy in ischemic stroke. Mol. Neurobiol. 49,
563–573 (2014).
Article  CAS  PubMed  Google Scholar 
231. Zheng, K. et al. Matrix metalloproteinases and their tissue
inhibitors in serum and cerebrospinal fluid of patients with
moderate and severe traumatic brain injury. Neurol. India 61,
606–609 (2013).
Article  PubMed  Google Scholar 
232. Ulrich, N. H., Dehmel, T., Wittsack, H. J., Kieseier, B. C. &
Seitz, R. J. Peripheral blood levels of matrix
metalloproteinase-9 predict lesion volume in acute stroke.
Neurol. Sci. 34, 379–382 (2013).


Article  PubMed  Google Scholar 
233. Svedin, P., Hagberg, H., Savman, K., Zhu, C. & Mallard, C.
Matrix metalloproteinase-9 gene knock-out protects the
immature brain after cerebral hypoxia–ischemia. J. Neurosci.
27, 1511–1518 (2007).
Article  CAS  PubMed  PubMed Central  Google Scholar 
234. Wang, X. et al. Effects of matrix metalloproteinase-9 gene
knock-out on morphological and motor outcomes after
traumatic brain injury. J. Neurosci. 20, 7037–7042 (2000).
Article  CAS  PubMed  PubMed Central  Google Scholar 
235. Asahi, M. et al. Effects of matrix metalloproteinase-9 gene
knock-out on the proteolysis of blood–brain barrier and white
matter components after cerebral ischemia. J. Neurosci. 21,
7724–7732 (2001).
Article  CAS  PubMed  PubMed Central  Google Scholar 
236. Gidday, J. M. et al. Leukocyte-derived matrix
metalloproteinase-9 mediates blood-brain barrier breakdown
and is proinflammatory after transient focal cerebral
ischemia. Am. J. Physiol. Heart Circ. Physiol. 289, H558–568
(2005).
Article  CAS  PubMed  Google Scholar 
237. Shichi, K. et al. Involvement of matrix metalloproteinase-
mediated proteolysis of neural cell adhesion molecule in the
development of cerebral ischemic neuronal damage. J.
Pharmacol. Exp. Ther. 338, 701–710 (2011).
Article  CAS  PubMed  Google Scholar 
238. Hu, Q. et al. Lentivirus-mediated transfer of MMP-9 shRNA
provides neuroprotection following focal ischemic brain
injury in rats. Brain Res. 1367, 347–359 (2011).
Article  CAS  PubMed  Google Scholar 


239. Romanic, A. M., White, R. F., Arleth, A. J., Ohlstein, E. H. &
Barone, F. C. Matrix metalloproteinase expression increases
after cerebral focal ischemia in rats: inhibition of matrix
metalloproteinase-9 reduces infarct size. Stroke 29, 1020–
1030 (1998).
Article  CAS  PubMed  Google Scholar 
240. Hu, Q. et al. Therapeutic application of gene silencing MMP-9
in a middle cerebral artery occlusion-induced focal ischemia
rat model. Exp. Neurol. 216, 35–46 (2009).
Article  CAS  PubMed  Google Scholar 
241. Verslegers, M., Lemmens, K., Van Hove, I. & Moons, L. Matrix
metalloproteinase-2 and -9 as promising benefactors in
development, plasticity and repair of the nervous system.
Progress Neurobiol. 105, 60–78 (2013).
Article  CAS  Google Scholar 
242. Asahi, M., Sumii, T., Fini, M. E., Itohara, S. & Lo, E. H. Matrix
metalloproteinase 2 gene knockout has no effect on acute
brain injury after focal ischemia. Neuroreport 12, 3003–3007
(2001).
Article  CAS  PubMed  Google Scholar 
243. Walker, E. J. & Rosenberg, G. A. TIMP-3 and MMP-3
contribute to delayed inflammation and hippocampal
neuronal death following global ischemia. Exp. Neurol. 216,
122–131 (2009).
Article  CAS  PubMed  Google Scholar 
244. Hadass, O. et al. Selective inhibition of matrix
metalloproteinase-9 attenuates secondary damage resulting
from severe traumatic brain injury. PLoS ONE 8, e76904
(2013).
Article  CAS  PubMed  PubMed Central  Google Scholar 


245. Jiang, J. Y. et al. MMP-9 inhibitor SB-3CT attenuates
behavioral impairments and hippocampal loss after traumatic
brain injury in rat. J. Neurotrauma 31, 1225–1234 (2014).
Article  PubMed  PubMed Central  Google Scholar 
246. Cui, J. et al. Inhibition of MMP-9 by a selective gelatinase
inhibitor protects neurovasculature from embolic focal
cerebral ischemia. Mol. Neurodegener. 7, 21 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
247. Ranasinghe, H. S. et al. Inhibition of MMP-9 activity
following hypoxic ischemia in the developing brain using a
highly specific inhibitor. Dev. Neurosci. 34, 417–427 (2012).
Article  CAS  PubMed  Google Scholar 
248. Guo, Z. D. et al. Matrix metalloproteinase 9 inhibition reduces
early brain injury in cortex after subarachnoid hemorrhage.
Acta Neurochir. Suppl. 110, 81–84 (2011).
PubMed  Google Scholar 
249. Burggraf, D., Trinkl, A., Dichgans, M. & Hamann, G. F.
Doxycycline inhibits MMPs via modulation of plasminogen
activators in focal cerebral ischemia. Neurobiol. Dis. 25, 506–
513 (2007).
Article  CAS  PubMed  Google Scholar 
250. Copin, J. C., Merlani, P., Sugawara, T., Chan, P. H. & Gasche,
Y. Delayed matrix metalloproteinase inhibition reduces
intracerebral hemorrhage after embolic stroke in rats. Exp.
Neurol. 213, 196–201 (2008).
Article  CAS  PubMed  PubMed Central  Google Scholar 
251. Lee, H., Park, J. W., Kim, S. P., Lo, E. H. & Lee, S. R.
Doxycycline inhibits matrix metalloproteinase-9 and laminin
degradation after transient global cerebral ischemia.
Neurobiol. Dis. 34, 189–198 (2009).


Article  CAS  PubMed  Google Scholar 
252. Pires, P. W. et al. Doxycycline, a matrix metalloprotease
inhibitor, reduces vascular remodeling and damage after
cerebral ischemia in stroke-prone spontaneously hypertensive
rats. Am. J. Physiol. Heart Circ. Physiol. 301, H87–H97 (2011).
Article  CAS  PubMed  PubMed Central  Google Scholar 
253. Wang, Z., Xue, Y., Jiao, H., Liu, Y. & Wang, P. Doxycycline-
mediated protective effect against focal cerebral ischemia-
reperfusion injury through the modulation of tight junctions
and PKCδ signaling in rats. J. Mol. Neurosci. 47, 89–100
(2012).
Article  CAS  PubMed  Google Scholar 
254. Yrjanheikki, J. et al. A tetracycline derivative, minocycline,
reduces inflammation and protects against focal cerebral
ischemia with a wide therapeutic window. Proc. Natl Acad.
Sci. USA 96, 13496–13500 (1999).
Article  CAS  PubMed  PubMed Central  Google Scholar 
255. Yrjanheikki, J., Keinanen, R., Pellikka, M., Hokfelt, T. &
Koistinaho, J. Tetracyclines inhibit microglial activation and
are neuroprotective in global brain ischemia. Proc. Natl Acad.
Sci. USA 95, 15769–15774 (1998).
Article  CAS  PubMed  PubMed Central  Google Scholar 
256. Bhatt, L. K. & Addepalli, V. Potentiation of aspirin-induced
cerebroprotection by minocycline: a therapeutic approach to
attenuate exacerbation of transient focal cerebral ischaemia.
Diab. Vasc. Dis. Res. 9, 25–34 (2012).
Article  PubMed  Google Scholar 
257. Pfefferkorn, T. & Rosenberg, G. A. Closure of the blood–brain
barrier by matrix metalloproteinase inhibition reduces rtPA-
mediated mortality in cerebral ischemia with delayed
reperfusion. Stroke 34, 2025–2030 (2003).


Article  PubMed  Google Scholar 
258. Walker, E. J. & Rosenberg, G. A. Divergent role for MMP-2 in
myelin breakdown and oligodendrocyte death following
transient global ischemia. J. Neurosci. Res. 88, 764–773
(2010).
CAS  PubMed  PubMed Central  Google Scholar 
259. Zhao, B. Q. et al. Role of matrix metalloproteinases in delayed
cortical responses after stroke. Nature Med. 12, 441–445
(2006).
Article  CAS  PubMed  Google Scholar 
260. Liu, W., Hendren, J., Qin, X. J., Shen, J. & Liu, K. J.
Normobaric hyperoxia attenuates early blood–brain barrier
disruption by inhibiting MMP-9-mediated occludin
degradation in focal cerebral ischemia. J. Neurochem. 108,
811–820 (2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 
261. Rosenberg, G. A., Estrada, E. Y. & Dencoff, J. E. Matrix
metalloproteinases and TIMPs are associated with blood–
brain barrier opening after reperfusion in rat brain. Stroke 29,
2189–2195 (1998).
Article  CAS  PubMed  Google Scholar 
262. Yang, Y., Estrada, E. Y., Thompson, J. F., Liu, W. &
Rosenberg, G. A. Matrix metalloproteinase-mediated
disruption of tight junction proteins in cerebral vessels is
reversed by synthetic matrix metalloproteinase inhibitor in
focal ischemia in rat. J. Cereb. Blood Flow Metab. 27, 697–709
(2007).
Article  CAS  PubMed  Google Scholar 
263. Sood, R. R., Taheri, S., Candelario-Jalil, E., Estrada, E. Y. &
Rosenberg, G. A. Early beneficial effect of matrix
metalloproteinase inhibition on blood–brain barrier


permeability as measured by magnetic resonance imaging
countered by impaired long-term recovery after stroke in rat
brain. J. Cereb. Blood Flow Metab. 28, 431–438 (2008).
Article  CAS  PubMed  Google Scholar 
264. Yang, Y. et al. Increased intranuclear matrix
metalloproteinase activity in neurons interferes with
oxidative DNA repair in focal cerebral ischemia. J.
Neurochem. 112, 134–149 (2010).
Article  CAS  PubMed  Google Scholar 
265. Amantea, D., Corasaniti, M. T., Mercuri, N. B., Bernardi, G. &
Bagetta, G. Brain regional and cellular localization of
gelatinase activity in rat that have undergone transient
middle cerebral artery occlusion. Neuroscience 152, 8–17
(2008).
Article  CAS  PubMed  Google Scholar 
266. Chen, W. et al. Matrix metalloproteinases inhibition provides
neuroprotection against hypoxia-ischemia in the developing
brain. J. Neurochem. 111, 726–736 (2009).
Article  CAS  PubMed  Google Scholar 
267. Gu, Z. et al. S-nitrosylation of matrix metalloproteinases:
signaling pathway to neuronal cell death. Science 297, 1186–
1190 (2002).
Article  CAS  PubMed  Google Scholar 
268. Lee, S. R. et al. Involvement of matrix metalloproteinase in
neuroblast cell migration from the subventricular zone after
stroke. J. Neurosci. 26, 3491–3495 (2006).
Article  CAS  PubMed  PubMed Central  Google Scholar 
269. Yang, Y. et al. Early inhibition of MMP activity in ischemic
rat brain promotes expression of tight junction proteins and
angiogenesis during recovery. J. Cereb. Blood Flow Metab. 33,


1104–1114 (2013).
Article  CAS  PubMed  PubMed Central  Google Scholar 
270. Mishiro, K. et al. A broad-spectrum matrix metalloproteinase
inhibitor prevents hemorrhagic complications induced by
tissue plasminogen activator in mice. Neuroscience 205, 39–48
(2012).
Article  CAS  PubMed  Google Scholar 
271. Nagel, S. et al. Selective MMP-inhibition with Ro 28–2653 in
acute experimental stroke — a magnetic resonance imaging
efficacy study. Brain Res. 1368, 264–270 (2011).
Article  CAS  PubMed  Google Scholar 
272. Thomsen, L. B. et al. Brain delivery systems via mechanism
independent of receptor-mediated endocytosis and
adsorptive-mediated endocytosis. Curr. Pharm. Biotechnol. 13,
2349–2354 (2012).
Article  CAS  PubMed  Google Scholar 
273. Guo, L., Ren, J. & Jiang, X. Perspectives on brain-targeting
drug delivery systems. Curr. Pharm. Biotechnol. 13, 2310–
2318 (2012).
Article  CAS  PubMed  Google Scholar 
274. Tang, Y. et al. MT1-MMP-dependent control of skeletal stem
cell commitment via a beta1-integrin/YAP/TAZ signaling
axis. Dev. Cell 25, 402–416 (2013).
Article  CAS  PubMed  PubMed Central  Google Scholar 
275. Dufour, A. & Overall, C. M. Missing the target: matrix
metalloproteinase antitargets in inflammation and cancer.
Trends Pharmacol. Sci. 34, 233–242 (2013).
Article  CAS  PubMed  Google Scholar 


276. Ghosh, D. et al. Paneth cell trypsin is the processing enzyme
for human defensin-5. Nature Immunol. 3, 583–590 (2002).
Article  CAS  Google Scholar 
277. Lindsey, M. L. & Zamilpa, R. Temporal and spatial expression
of matrix metalloproteinases and tissue inhibitors of
metalloproteinases following myocardial infarction.
Cardiovascular Ther. 30, 31–41 (2012).
Article  CAS  Google Scholar 
278. Scherer, R. L., McIntyre, J. O. & Matrisian, L. M. Imaging
matrix metalloproteinases in cancer. Cancer Metastasis Rev.
27, 679–690 (2008).
Article  PubMed  Google Scholar 
279. Yang, K. et al. Visualization of protease activity in vivo using
an activatable photo-acoustic imaging probe based on CuS
nanoparticles. Theranostics 4, 134–141 (2014).
Article  CAS  PubMed  PubMed Central  Google Scholar 
280. Waschkau, B., Faust, A., Schafers, M. & Bremer, C.
Performance of a new fluorescence-labeled MMP inhibitor to
image tumor MMP activity in vivo in comparison to an MMP-
activatable probe. Contrast Media Mol. Imag. 8, 1–11 (2013).
Article  CAS  Google Scholar 
281. Matusiak, N. et al. Probes for non-invasive matrix
metalloproteinase-targeted imaging with PET and SPECT.
Curr. Pharm. Design 19, 4647–4672 (2013).
Article  CAS  Google Scholar 
282. Fingleton, B. Matrix metalloproteinases as valid clinical
targets. Curr. Pharm. Design 13, 333–346 (2007).
Article  CAS  Google Scholar 


283. Roy, R., Yang, J. & Moses, M. A. Matrix metalloproteinases as
novel biomarkers and potential therapeutic targets in human
cancer. J. Clin. Oncol. 27, 5287–5297 (2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 
284. Hayden, D. M., Forsyth, C. & Keshavarzian, A. The role of
matrix metalloproteinases in intestinal epithelial wound
healing during normal and inflammatory states. J. Surg. Res.
168, 315–324 (2011).
Article  CAS  PubMed  Google Scholar 
285. Tugwood, J. D. et al. Fibrodysplasia induced in dog skin by a
matrix metalloproteinase (MMP) inhibitor — a mechanistic
analysis. Toxicol. Sci. 127, 236–245 (2012).
Article  CAS  PubMed  Google Scholar 
286. Moake, J. L. von Willebrand factor, ADAMTS-13, and
thrombotic thrombocytopenic purpura. Seminars Hematol. 41,
4–14 (2004).
Article  CAS  Google Scholar 
287. Sela-Passwell, N., Trahtenherts, A., Kruger, A. & Sagi, I. New
opportunities in drug design of metalloproteinase inhibitors:
combination between structure-function experimental
approaches and systems biology. Expert Opin. Drug Discov. 6,
527–542 (2011).
Article  CAS  PubMed  Google Scholar 
288. Devel, L. et al. Third generation of matrix metalloprotease
inhibitors: gain in selectivity by targeting the depth of the S1′
cavity. Biochimie 92, 1501–1508 (2010).
Article  CAS  PubMed  Google Scholar 
289. Kothapalli, R. et al. Cheminformatics-based drug design
approach for identification of inhibitors targeting the
characteristic residues of MMP-13 hemopexin domain. PLoS


ONE 5, e12494 (2010).
Article  PubMed  PubMed Central  CAS  Google Scholar 
290. Hu, J. et al. Inhibition of lethal endotoxin shock with an L-
pyridylalanine containing metalloproteinase inhibitor selected
by high-throughput screening of a new peptide library. Comb.
Chem. High Throughput Screen. 9, 599–611 (2006).
Article  CAS  PubMed  Google Scholar 
291. Mannello, F. & Medda, V. Nuclear localization of matrix
metalloproteinases. Progress Histochem. Cytochem. 47, 27–58
(2012).
Article  Google Scholar 
292. Cauwe, B. & Opdenakker, G. Intracellular substrate cleavage:
a novel dimension in the biochemistry, biology and pathology
of matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 45,
351–423 (2010).
Article  CAS  PubMed  Google Scholar 
293. Soslau, G. et al. Intracellular matrix metalloproteinase-2
(MMP-2) regulates human platelet activation via hydrolysis of
talin. Thromb. Haemostasis 111, 140–153 (2014).
Article  CAS  Google Scholar 
294. Solli, A. I., Fadnes, B., Winberg, J. O., Uhlin-Hansen, L. &
Hadler-Olsen, E. Tissue- and cell-specific co-localization of
intracellular gelatinolytic activity and matrix
metalloproteinase 2. J. Histochem. Cytochem. 61, 444–461
(2013).
Article  PubMed  PubMed Central  CAS  Google Scholar 
295. Sawicki, G. Intracellular regulation of matrix
metalloproteinase-2 activity: new strategies in treatment and
protection of heart subjected to oxidative stress. Scientifica
2013, 130451 (2013).


Article  PubMed  PubMed Central  CAS  Google Scholar 
296. Zuo, X., Pan, W., Feng, T., Shi, X. & Dai, J. Matrix
metalloproteinase 3 promotes cellular anti-dengue virus
response via interaction with transcription factor NFκB in cell
nucleus. PLoS ONE 9, e84748 (2014).
Article  PubMed  PubMed Central  CAS  Google Scholar 
297. Marchant, D. J. et al. A new transcriptional role for matrix
metalloproteinase-12 in antiviral immunity. Nature Med. 20,
493–502 (2014).
Article  CAS  PubMed  Google Scholar 
298. Muyldermans, S. Nanobodies: natural single-domain
antibodies. Annu. Rev. Biochem. 82, 775–797 (2013).
Article  CAS  PubMed  Google Scholar 
299. Holmbeck, K. et al. MT1-MMP-deficient mice develop
dwarfism, osteopenia, arthritis, and connective tissue disease
due to inadequate collagen turnover. Cell 99, 81–92 (1999).
Article  CAS  PubMed  Google Scholar 
300. Zhou, Z. et al. Impaired endochondral ossification and
angiogenesis in mice deficient in membrane-type matrix
metalloproteinase I. Proc. Natl Acad. Sci. USA 97, 4052–4057
(2000).
Article  CAS  PubMed  PubMed Central  Google Scholar 
301. Kim, J. W. et al. MMP-20 mutation in autosomal recessive
pigmented hypomaturation amelogenesis imperfecta. J. Med.
Genet. 42, 271–275 (2005).
Article  CAS  PubMed  PubMed Central  Google Scholar 
302. Papagerakis, P. et al. Premature stop codon in MMP20
causing amelogenesis imperfecta. J. Dental Res. 87, 56–59
(2008).


Article  CAS  Google Scholar 
303. Iwasaki, M. et al. Anti-invasive effect of MMI-166, a new
selective matrix metalloproteinase inhibitor, in cervical
carcinoma cell lines. Gynecol. Oncol. 85, 103–107 (2002).
Article  CAS  PubMed  Google Scholar 
Download references
Acknowledgements
This work was supported by FWO Vlaanderen, Belgium and by the
IAP initiative of Belgian Society Policy. The authors thank A.
Bredan for editing the manuscript.
Author information
Authors and Affiliations
1. Inflammation Research Center — VIB, Rijvisschestraat 120,
Ghent, 9052, Belgium
Roosmarijn E. Vandenbroucke & Claude Libert
2. Department of Biomedical Molecular Biology — Ghent
University, FSVM Building, Technologiepark 927, Zwijnaarde,
Ghent, B-9052, Belgium
Roosmarijn E. Vandenbroucke & Claude Libert
Authors
1. Roosmarijn E. Vandenbroucke
View author publications
Search author on:PubMed Google Scholar


2. Claude Libert
View author publications
Search author on:PubMed Google Scholar
Corresponding author
Correspondence to Claude Libert.
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (table)
Overview of the different mouse and human MMPs (PDF 168 kb)
PowerPoint slides
PowerPoint slide for Fig. 1
PowerPoint slide for Fig. 2
PowerPoint slide for Fig. 3
PowerPoint slide for Fig. 4
PowerPoint slide for Table 1
PowerPoint slide for Table 2


PowerPoint slide for Table 3
PowerPoint slide for Table 4
Rights and permissions
Reprints and permissions
About this article
[image]
Cite this article
Vandenbroucke, R., Libert, C. Is there new hope for therapeutic
matrix metalloproteinase inhibition?. Nat Rev Drug Discov 13, 904–
927 (2014). https://doi.org/10.1038/nrd4390
Download citation
•  Published: 07 November 2014
•  Issue date: December 2014
•  DOI: https://doi.org/10.1038/nrd4390
Share this article
Anyone you share the following link with will be able to read this
content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy shareable link to clipboard


Provided by the Springer Nature SharedIt content-sharing initiative
This article is cited by
•  Targeting cholesterol impairs cell invasion of all
breast cancer types
○  Mauriane Maja
○  Marie Verfaillie
○  Donatienne Tyteca
Cancer Cell International (2024)
•  Identification of Circulating Inflammatory
Proteins Associated with Calcific Aortic Valve
Stenosis by Multiplex Analysis
○  Rui Lin
○  Yuexin Zhu
○  Jie Du
Cardiovascular Toxicology (2024)
•  Exploiting E3 ubiquitin ligases to reeducate the
tumor microenvironment for cancer therapy
○  Xian-Miao Li
○  Zhen-Yu Zhao
○  Jia Hu
Experimental Hematology & Oncology (2023)
•  Trio-pharmacophore DNA-encoded chemical
library for simultaneous selection of fragments
and linkers
○  Meiying Cui
○  Dzung Nguyen


○  Yixin Zhang
Nature Communications (2023)
•  Signaling pathways in vascular function and
hypertension: molecular mechanisms and
therapeutic interventions
○  Jun Ma
○  Yanan Li
○  Xiaoping Chen
Signal Transduction and Targeted Therapy (2023)
 Access through your institution
Buy or subscribe
Advertisement
[image]
Explore content
•  Research articles
•  Reviews & Analysis
•  News & Comment
•  Videos
•  Current issue
•  Collections
•  Follow us on Facebook
•  Follow us on Twitter
•  Subscribe
•  Sign up for alerts
•  RSS feed


About the journal
•  Aims & Scope
•  Journal Information
•  Editorial policies
•  About the Editors
•  Reviews Cross-Journal Editorial Team
•  Journal Credits
•  Editorial input and checks
•  Editorial Values Statement
•  Journal Metrics
•  Publishing model
•  Conferences
•  Posters
•  Web Feeds
•  Contact
Publish with us
•  For Authors
•  For Referees
•  Submit manuscript
Search
Search articles by subject, keyword or author
Show results from All journals This journal
Search
Advanced search
Quick links
•  Explore articles by subject
•  Find a job
•  Guide to authors


•  Editorial policies
Nature Reviews Drug Discovery (Nat Rev Drug Discov)
ISSN 1474-1784 (online)
ISSN 1474-1776 (print)
nature.com sitemap
About Nature Portfolio
•  About us
•  Press releases
•  Press office
•  Contact us
Discover content
•  Journals A-Z
•  Articles by subject
•  protocols.io
•  Nature Index
Publishing policies
•  Nature portfolio policies
•  Open access
Author & Researcher services
•  Reprints & permissions
•  Research data
•  Language editing
•  Scientific editing
•  Nature Masterclasses
•  Research Solutions


Libraries & institutions
•  Librarian service & tools
•  Librarian portal
•  Open research
•  Recommend to library
Advertising & partnerships
•  Advertising
•  Partnerships & Services
•  Media kits
•  Branded content
Professional development
•  Nature Awards
•  Nature Careers
•  Nature Conferences
Regional websites
•  Nature Africa
•  Nature China
•  Nature India
•  Nature Japan
•  Nature Middle East
•  Privacy Policy
•  Use of cookies
•  Your privacy choices/Manage cookies
•  Legal notice
•  Accessibility statement
•  Terms & Conditions
•  Your US state privacy rights
[image]
© 2025 Springer Nature Limited


 Close
[image]
Sign up for the Nature Briefing: Translational Research newsletter —
top stories in biotechnology, drug discovery and pharma.
Email address


Sign up
I agree my information will be processed in accordance with the
Nature and Springer Nature Limited Privacy Policy.
 Close
Get what matters in translational research, free to your inbox
weekly. Sign up for Nature Briefing: Translational Research
[image]


